Billion to One claims to have nearly 20% market share in its target market.

Billion to One believes its technology could eventually be used for early-stage cancer detection before a tumor reaches stage one, an achievement they consider the "holy grail" of the field.

Approximately 20% of stage 1-2 cancer patients have microscopic residual disease after curative intent surgery, which is undetectable by current imaging scans.

Billion to One incorporated AI and computer vision into its lab process to accelerate sample accessioning, which had become an operational bottleneck.

Billion to One processes more than 600,000 genetic tests per year.

In a case study, Billion to One's North Star Select liquid biopsy test identified microsatellite instability in a metastatic colorectal cancer patient, a finding missed by a traditional tissue biopsy,...

Two months after launching its first product, Billion to One had only one physician as a customer, ordering one to two tests per week.

Billion to One structures its R&D organization into small teams, each led by an interdisciplinary principal scientist with two or three research associates, who report directly to the company's founde...

Billion to One's core technology involves adding synthetic DNA molecules to a patient's sample before amplification to computationally measure and remove noise from the sequencing data.

Billion to One is operating as a profitable company.

The founders of Billion to One believe that developing an early cancer detection test from the outset would require raising over $1 billion before generating any revenue.

Billion to One anticipates launching its ultra-sensitive minimal residual disease (MRD) test for stage 1 and 2 cancer patients in less than a year.

Billion to One's first fundraising round of $300,000 took six months to close and was raised in increments as small as $10,000.

Billion to One believes its current lab facility has the capacity to process nearly 2 million tests per year.

Billion to One's long-term strategy, set one year after its founding, involved a three-step market entry: prenatal genetics, then late-stage cancer diagnostics, and finally early-stage cancer screenin...